API Holdings, the parent company of PharmEasy, has delivered one of its strongest financial performances in recent years, highlighting the success of its transformation strategy. Once known for prioritizing rapid customer acquisition and aggressive expansion, the company has now shifted its focus toward operational discipline, profitability, and sustainable growth.<\/p>\n\n\n\n
The FY26 results demonstrate that this strategy is beginning to pay off. Strong revenue growth, expanding gross margins, lower operating expenses, improved working capital management, and a positive EBITDA collectively indicate that API Holdings is entering a new phase of financial stability.<\/p>\n\n\n\n
For investors tracking PharmEasy Unlisted Shares and evaluating a broader Pre IPO Investment in India’s digital healthcare space, these results provide important insights into how the company is evolving and whether it is moving closer to creating long-term shareholder value.<\/p>\n\n\n\n
FY26 was a landmark year for API Holdings. The company reported consolidated revenue of \u20b96,869 crore, representing a 14.3% year-on-year increase over FY25. Revenue remained consistent across all four quarters, reflecting healthy demand across its healthcare businesses and improved execution.<\/p>\n\n\n\n
More importantly, the company successfully turned around its operating profitability. EBITDA improved from a loss of \u20b9231 crore in FY25 to a profit of \u20b962.5 crore in FY26, marking one of the most significant improvements in the company’s financial history.<\/p>\n\n\n\n
This turnaround was not driven by one-time gains but by structural improvements across the business, including better procurement, stronger gross margins, disciplined spending, and improved operating efficiencies. For those weighing Unlisted Company Shares as part of a diversified portfolio, this shift from cash-burn to discipline is the headline data point.<\/p>\n\n\n\n
The table below summarises the key FY26 metrics at a glance:<\/p>\n\n\n\n Unlike many digital healthcare companies that depend on a single revenue stream, API Holdings has built a diversified healthcare ecosystem.<\/p>\n\n\n\n Its operations include:<\/p>\n\n\n\n This diversified model allows the company to generate revenue from consumers, pharmacies, hospitals, diagnostic centres, and healthcare institutions, creating multiple growth drivers within a single platform.<\/p>\n\n\n\n The most notable achievement during FY26 was the company’s return to positive EBITDA.<\/p>\n\n\n\n Only a year ago, API Holdings was reporting substantial operating losses. During FY26, management focused on improving contribution margins, reducing unnecessary operating expenses, strengthening procurement processes, and increasing operational efficiency across business units. As a result, EBITDA turned positive for the full year despite continued investments in business growth.<\/p>\n\n\n\n This milestone demonstrates that the company is increasingly balancing growth with profitability \u2014 a transition that investors have been waiting for over the past few years.<\/p>\n\n\n\n One of the strongest indicators of improving business quality is the expansion in gross margins.<\/p>\n\n\n\n API Holdings increased its annual gross margin from 18.6% in FY25 to 19.8% in FY26, while Q4 FY26 recorded an even stronger gross margin of 21.0%.<\/p>\n\n\n\n Higher gross margins generally indicate stronger procurement efficiencies, improved pricing discipline, a better product mix, and greater operating leverage.<\/p>\n\n\n\n The continued improvement suggests that the company is becoming more efficient in generating profits from every rupee of revenue.<\/p>\n\n\n\n Revenue growth alone does not create shareholder value unless accompanied by cost discipline.<\/p>\n\n\n\n API Holdings reduced its operating expenses despite expanding its business. The operating expense ratio improved significantly from 22.4% in FY25 to 18.7% in FY26.<\/p>\n\n\n\n This reflects management’s focus on improving productivity, optimizing logistics, rationalizing marketing expenditure, and increasing operational efficiencies across business segments.<\/p>\n\n\n\n Such improvements are especially important for digital healthcare companies, where profitability often depends on maintaining efficient customer acquisition and fulfillment costs.<\/p>\n\n\n\n Another positive development during FY26 was the continued improvement in working capital efficiency. Working capital days reduced to 39 days, compared to 53 days in FY24.<\/p>\n\n\n\n Lower working capital requirements improve cash flow, reduce financing needs, and strengthen overall financial flexibility.<\/p>\n\n\n\n This improvement reflects better inventory management, improved receivable collections, and tighter control over operational processes.<\/p>\n\n\n\n The B2B pharmaceutical distribution business continued to be the backbone of API Holdings.<\/p>\n\n\n\n The segment generated revenue of \u20b94,089 crore during FY26, registering 15% annual growth.<\/p>\n\n\n\n Along with higher revenue, the segment also reported stronger gross margins and significantly lower operating expenses. EBITDA improved from a sizeable loss in FY25 to near breakeven during FY26, reflecting the benefits of scale and operational improvements.<\/p>\n\n\n\n As the distribution business continues expanding across pharmacies, hospitals, and healthcare institutions, it is expected to remain one of the company’s primary growth engines.<\/p>\n\n\n\n The PharmEasy consumer business also reported encouraging progress.<\/p>\n\n\n\n Revenue increased to \u20b91,334 crore, supported by higher order volumes and improved customer engagement.<\/p>\n\n\n\n Gross margins expanded to 25.7%, while EBITDA losses narrowed significantly.<\/p>\n\n\n\n Perhaps the most encouraging trend is the steady improvement in EBITDA margins \u2014 from -16.3% in FY24 to -1.5% during Q4 FY26.<\/p>\n\n\n\n Although the consumer platform has not yet achieved positive EBITDA, the improvement demonstrates that customer acquisition costs, fulfillment efficiencies, and contribution margins are steadily improving.<\/p>\n\n\n\n Among all business verticals, Thyrocare remained the strongest performer.<\/p>\n\n\n\n The diagnostics business reported revenue of \u20b9829 crore, representing more than 20% annual growth.<\/p>\n\n\n\n Its EBITDA reached \u20b9280 crore, while EBITDA margins remained exceptionally strong at 33.8%.<\/p>\n\n\n\n The diagnostics business continues to benefit from economies of scale, an established laboratory network, and strong brand recognition.<\/p>\n\n\n\n For API Holdings, Thyrocare provides stable cash generation and acts as an important contributor to consolidated profitability.<\/p>\n\n\n\n The hospital procurement platform, Aknamed, remained under restructuring during FY26.<\/p>\n\n\n\n While revenue witnessed a marginal decline, management significantly reduced operating expenses, resulting in a substantial improvement in EBITDA losses.<\/p>\n\n\n\n Although the business has not yet achieved profitability, the reduction in losses indicates that operational restructuring is moving in the right direction.<\/p>\n\n\n\n API Holdings has evolved into an integrated healthcare ecosystem rather than just an online pharmacy.<\/p>\n\n\n\n Today, its businesses collectively serve:<\/p>\n\n\n\n This diversified ecosystem creates multiple revenue opportunities while allowing cross-selling between businesses such as PharmEasy and Thyrocare.<\/p>\n\n\n\n Several factors stand out from the FY26 results:<\/p>\n\n\n\n Together, these developments indicate that the company’s turnaround is becoming increasingly broad-based rather than being dependent on any single business segment.<\/p>\n\n\n\n Q1. What was API Holdings’ consolidated revenue in FY26?<\/strong> Q2. Did API Holdings turn EBITDA positive in FY26?<\/strong> Q3. Which business segment was the strongest profit contributor in FY26?<\/strong> API Holdings’ FY26 performance represents one of the most meaningful operational turnarounds seen in India’s digital healthcare sector over the past few years.<\/p>\n\n\n\n The transition from EBITDA losses to profitability, combined with healthy revenue growth, expanding gross margins, disciplined cost management, and improving working capital efficiency, reflects a business that is becoming financially stronger and more sustainable.<\/p>\n\n\n\n The B2B business continues to provide scale, Thyrocare generates healthy profitability, while the PharmEasy platform is steadily moving closer to operating breakeven. If management continues executing with the same financial discipline, API Holdings could be well-positioned for its next phase of growth.<\/p>\n\n\n\n For investors tracking PharmEasy Unlisted Shares and looking to Invest in Unlisted Companies ahead of a potential listing, FY26 marks an important milestone in the company’s transformation journey. Those looking to Buy Unlisted Shares of PharmEasy, or simply track the current Unlisted Share Price, can find more detail through WWIPL. While achieving consistent net profitability remains the next major objective, the operational progress reported during the year provides encouraging signs that the business is moving in the right direction.<\/p>\n\n\n\n The information provided in this article is intended solely for educational and informational purposes and should not be construed as investment advice or a recommendation to buy or sell shares. Investors should evaluate their financial objectives and consult a qualified financial advisor before making any investment decisions.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":" Introduction API Holdings, the parent company of PharmEasy, has delivered one of its strongest financial performances in recent years, highlighting the success of its transformation strategy. Once known for prioritizing rapid customer acquisition and aggressive expansion, the company has now shifted its focus toward operational discipline, profitability, and sustainable growth. The FY26 results demonstrate that … API Holdings Q4 FY26 Results: From Cost Optimisation to Profitability \u2014 Is PharmEasy’s Parent Company Ready for Its Next Growth Phase?<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-673","post","type-post","status-publish","format-standard","hentry","category-unlisted-company"],"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/wwipl.com\/blog\/wp-json\/wp\/v2\/posts\/673","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wwipl.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wwipl.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wwipl.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/wwipl.com\/blog\/wp-json\/wp\/v2\/comments?post=673"}],"version-history":[{"count":2,"href":"https:\/\/wwipl.com\/blog\/wp-json\/wp\/v2\/posts\/673\/revisions"}],"predecessor-version":[{"id":690,"href":"https:\/\/wwipl.com\/blog\/wp-json\/wp\/v2\/posts\/673\/revisions\/690"}],"wp:attachment":[{"href":"https:\/\/wwipl.com\/blog\/wp-json\/wp\/v2\/media?parent=673"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wwipl.com\/blog\/wp-json\/wp\/v2\/categories?post=673"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wwipl.com\/blog\/wp-json\/wp\/v2\/tags?post=673"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Metric<\/strong><\/td> FY25<\/strong><\/td> FY26<\/strong><\/td> Key Highlight<\/strong><\/td><\/tr><\/thead> Consolidated Revenue<\/td> \u20b96,010 crore<\/td> \u20b96,869 crore<\/td> 14.3% YoY growth<\/td><\/tr> EBITDA<\/td> -\u20b9231 crore<\/td> +\u20b962.5 crore<\/td> Turned positive for the full year<\/td><\/tr> Gross Margin<\/td> 18.6%<\/td> 19.8% (Q4: 21.0%)<\/td> Improved procurement and pricing discipline<\/td><\/tr> Operating Expense Ratio<\/td> 22.4%<\/td> 18.7%<\/td> Lower opex despite revenue growth<\/td><\/tr> Working Capital Days<\/td> 53 days (FY24)<\/td> 39 days<\/td> Stronger cash flow efficiency<\/td><\/tr> B2B Distribution Revenue<\/td> \u2014<\/td> \u20b94,089 crore<\/td> 15% YoY growth; EBITDA near breakeven<\/td><\/tr> PharmEasy Consumer Revenue<\/td> \u2014<\/td> \u20b91,334 crore<\/td> Gross margin 25.7%; EBITDA margin -1.5% in Q4<\/td><\/tr> Thyrocare Revenue<\/td> \u2014<\/td> \u20b9829 crore<\/td> >20% YoY growth; EBITDA margin 33.8%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n Revenue Drivers: PharmEasy, Thyrocare, and B2B Growth<\/h2>\n\n\n\n
\n
EBITDA Turnaround Reflects Better Business Economics<\/h2>\n\n\n\n
Gross Margin Expansion Strengthens Profitability<\/h2>\n\n\n\n
Cost Optimization Continues to Deliver Results<\/h2>\n\n\n\n
Working Capital Management Continues to Improve<\/h2>\n\n\n\n
B2B Business Remains the Largest Revenue Contributor<\/h2>\n\n\n\n
PharmEasy Consumer Platform Moves Closer to Profitability<\/h2>\n\n\n\n
Thyrocare Continues to Deliver Strong Profitability<\/h2>\n\n\n\n
Aknamed Continues Its Restructuring Journey<\/h2>\n\n\n\n
What Makes API Holdings Different?<\/h2>\n\n\n\n
\n
Key Positives for Investors<\/h2>\n\n\n\n
\n
Frequently Asked Questions<\/h2>\n\n\n\n
API Holdings reported consolidated revenue of \u20b96,869 crore in FY26, a 14.3% increase over FY25.<\/p>\n\n\n\n
Yes. EBITDA improved from a loss of \u20b9231 crore in FY25 to a profit of \u20b962.5 crore in FY26, marking the company’s return to full-year operating profitability.<\/p>\n\n\n\n
Thyrocare was the strongest performer, with revenue of \u20b9829 crore (over 20% annual growth) and an EBITDA margin of 33.8%.<\/p>\n\n\n\nPharmEasy Unlisted Share Outlook: What to Watch Next<\/h2>\n\n\n\n
Disclaimer<\/h2>\n\n\n\n